Display options
Cite
Kakazu E, Kondo Y, Ninomiya M, et al. The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH). Hepatol Int. 2012;7(2):577-85doi: 10.1007/s12072-012-9395-y.
Kakazu, E., Kondo, Y., Ninomiya, M., Kimura, O., Nagasaki, F., Ueno, Y., & Shimosegawa, T. (2013). The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH). Hepatology international, 7(2), 577-85. https://doi.org/10.1007/s12072-012-9395-y
Kakazu, Eiji, et al. "The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH)." Hepatology international vol. 7,2 (2013): 577-85. doi: https://doi.org/10.1007/s12072-012-9395-y
Kakazu E, Kondo Y, Ninomiya M, Kimura O, Nagasaki F, Ueno Y, Shimosegawa T. The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH). Hepatol Int. 2013 Jun;7(2):577-85. doi: 10.1007/s12072-012-9395-y. Epub 2012 Aug 14. PMID: 26201790.
Copy Download .nbib Format: NLM
Share it on

Hepatol Int. 2013 Jun;7(2):577-85. doi: 10.1007/s12072-012-9395-y. Epub 2012 Aug 14.

The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH).

Hepatology international

Eiji Kakazu, Yasuteru Kondo, Masashi Ninomiya, Osamu Kimura, Futoshi Nagasaki, Yoshiyuki Ueno, Tooru Shimosegawa

Affiliations

  1. Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aobaku, Sendai, 980-8574, Japan. [email protected].
  2. Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aobaku, Sendai, 980-8574, Japan.
  3. Department of Gastroenterology, Sendai City Hospital, 3-1, Shimizukoji, Wakabayashiku, Sendai, Miyagi, 984-8501, Japan.
  4. Department of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.

PMID: 26201790 DOI: 10.1007/s12072-012-9395-y

Abstract

BACKGROUND AND AIMS: The peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand, piglitazone, enhances the degradation of branched-chain amino acids (BCAAs) in adipose tissue. However, it remains unknown whether pioglitazone influences the plasma amino acids (AA) profile in patients with nonalcoholic steatohepatitis (NASH). Thus, we investigated the relation between the therapeutic effect and the AA profile in NASH patients with a prospective study.

METHODS: We randomized 25 histologically proven NASH patients to diet treatment only or diet treatment plus pioglitazone (15 mg/day), and investigated the biological data for 24 months. We measured the concentrations of AAs and compared them between the beginning and the end of the study.

RESULTS: Compared with the diet only group, pioglitazone therapy was associated with an increase in body weight (mean change -1.03 vs. +3.8 kg; p = 0.027) and subcutaneous fat (-3.7 vs. +45.7 cm(2); p = 0.056), and decreased ALT levels (-0.6 vs. -38.4 IU/L; p = 0.029) and HbA1c (0.33 vs. -0.29 %; p = 0.016). Regarding the AA profile, L-isoleucine, L-leucine, L-histidine, and L-lysine were significantly reduced in patients treated with pioglitazone. Furthermore, L-leucine was significantly reduced compared with those in the diet only group (mean change -34.8 vs. +4.12 nmol/mL; p = 0.032). Interestingly, there was a significant correlation between the changes in BCAAs, especially L-leucine, and those in ALT regardless of treatment with pioglitazone.

CONCLUSIONS: Pioglitazone therapy in NASH subjects significantly reduced the plasma BCAA level and the degradation was closely related to the improvement of the ALT levels. These results suggest that pioglitazone improves insulin resistance and BCAA metabolism in NASH patients.

Keywords: Branched-chain amino acids; Nonalcoholic steatohepatitis; PPAR-γ; Pioglitazone

References

  1. Anal Biochem. 1982 Nov 15;127(1):17-24 - PubMed
  2. Hepatology. 2003 Apr;37(4):917-23 - PubMed
  3. Metabolism. 1991 Jan;40(1):51-8 - PubMed
  4. N Engl J Med. 1969 Oct 9;281(15):811-6 - PubMed
  5. J Hepatol. 2010 Feb;52(2):206-10 - PubMed
  6. J Gastroenterol. 2008;43(9):720-8 - PubMed
  7. Cell Metab. 2009 Apr;9(4):311-26 - PubMed
  8. Biochem Int. 1991 Dec;25(5):797-806 - PubMed
  9. Diabetes Care. 2011 Apr;34(4):916-22 - PubMed
  10. Gastroenterology. 2002 Jun;122(7):1924-40 - PubMed
  11. Dig Liver Dis. 2008 May;40(5):371-8 - PubMed
  12. J Immunol. 2007 Nov 15;179(10):7137-46 - PubMed
  13. Hepatology. 2005 Jun;41(6):1313-21 - PubMed
  14. Gut. 1982 May;23(5):362-70 - PubMed
  15. N Engl J Med. 2006 Nov 30;355(22):2297-307 - PubMed
  16. Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1552-63 - PubMed
  17. Gastroenterology. 2008 Oct;135(4):1176-84 - PubMed
  18. J Clin Invest. 2003 Aug;112(4):608-18 - PubMed
  19. Diabetes. 1997 Sep;46(9):1393-9 - PubMed
  20. Mayo Clin Proc. 1980 Jul;55(7):434-8 - PubMed
  21. Hepatology. 2010 Jan;51(1):121-9 - PubMed
  22. BMJ. 2010 Mar 23;340:c332 - PubMed
  23. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18745-50 - PubMed
  24. Hepatology. 2008 Nov;48(5):1718-23 - PubMed
  25. N Engl J Med. 2010 May 6;362(18):1675-85 - PubMed
  26. Gut. 1978 Nov;19(11):1068-73 - PubMed
  27. Hepatology. 2008 Feb;47(2):592-5 - PubMed
  28. Diabetes Care. 2011 Jun;34(6):1369-71 - PubMed
  29. Nat Med. 2011 Apr;17(4):448-53 - PubMed
  30. Hepatology. 2008 Feb;47(2):380-4 - PubMed
  31. J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91 - PubMed
  32. Am J Clin Nutr. 2008 May;87(5):1141-7 - PubMed
  33. Am J Clin Nutr. 2007 Aug;86(2):285-300 - PubMed
  34. Hepatology. 2008 Aug;48(2):442-8 - PubMed
  35. Hepatology. 2009 Dec;50(6):1936-45 - PubMed
  36. Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E164-74 - PubMed
  37. J Clin Invest. 2007 Jun;117(6):1658-69 - PubMed
  38. Biochem Biophys Res Commun. 2004 Feb 27;315(1):187-95 - PubMed
  39. Diabetes. 2001 Aug;50(8):1863-71 - PubMed
  40. Cell. 1998 Apr 17;93(2):241-52 - PubMed

Publication Types